Portal de Periódicos da CAPES

Annexin‐A1: The culprit or the solution?

2022; Wiley; Volume: 166; Issue: 1 Linguagem: Inglês

10.1111/imm.13455

1365-2567

Lauren Kelly, Sarah McGrath, Lewis Rodgers, Kathryn McCall, Aysın Tulunay Virlan, Fiona C. Dempsey, Scott Crichton, Carl S. Goodyear,

Biomarkers in Disease Mechanisms

Abstract Annexin‐A1 has a well‐defined anti‐inflammatory role in the innate immune system, but its function in adaptive immunity remains controversial. This glucocorticoid‐induced protein has been implicated in a range of inflammatory conditions and cancers, as well as being found to be overexpressed on the T cells of patients with autoimmune disease. Moreover, the formyl peptide family of receptors, through which annexin‐A1 primarily signals, has also been implicated in these diseases. In contrast, treatment with recombinant annexin‐A1 peptides resulted in suppression of inflammatory processes in murine models of inflammation. This review will focus on what is currently known about annexin‐A1 in health and disease and discuss the potential of this protein as a biomarker and therapeutic target.